Latest Lung volume reduction surgery Stories
MOUNTAIN VIEW, Calif., Feb. 25, 2013 /PRNewswire/ -- PneumRx, Inc., a leader in interventional pulmonology, announced the first U.S. patients treated with PneumRx's Lung Volume Reduction Coils (LVRCs) for severe emphysema. Dr. Charlie Strange, of the Medical University of South Carolina, and Dr. Frank Sciurba, of the University of Pittsburgh and UPMC, treated the first US patients in the FDA-approved RENEW Study. The RePneu® LVRC, a minimally invasive medical implant designed to...
MOUNTAIN VIEW, Calif., Dec. 17, 2012 /PRNewswire/ -- PneumRx, Inc., a leader in interventional pulmonology, announced today that University Medical Center Groningen has enrolled and treated the first patients in the FDA-approved RENEW pivotal trial to evaluate the RePneu Lung Volume Reduction Coil (LVRC). The RePneu LVRC, a minimally invasive medical implant designed to treat the symptoms of severe emphysema, is intended to improve lung function, exercise ability and quality of life...
Northwestern Medicine® is the only center in Chicago participating in this trial CHICAGO, Nov. 27, 2012 /PRNewswire-USNewswire/ -- November is Chronic Obstructive Pulmonary Disease (COPD) Awareness Month. COPD, also known as emphysema, is the third leading cause of death in the United States, only behind heart disease and cancer. Right now, the only studied interventions that prolong life for patients with severe COPD are supplemental oxygen in people with low oxygen levels and lung...
MOUNTAIN VIEW, Calif., July 30, 2012 /PRNewswire/ -- PneumRx, Inc. (www.pneumrx.com), a leader in the field of interventional pulmonology, today announced that the French Ministry of Health has approved a cost-effectiveness study of the RePneu Lung Volume Reduction Coil (RePneu LVRC) in France. The Ministry of Health agreed to fund the study under the soutien aux techniques innovantes couteuses (STIC) program, which provides government funding for innovative medical technologies...
A tiny, resilient metal wire designed to gather and compress diseased lung tissue may offer relief to patients with severe heterogeneous emphysema, a subtype of the disease that involves specific, usually isolated areas of the lungs, according to the results of a multicenter international trial conducted in the Netherlands, Germany and France. The wire, called a lung volume reduction coil (LVRC), can be easily implanted and is designed to take the place of more invasive procedures used to...
MOUNTAIN VIEW, Calif., May 21, 2012 /PRNewswire/ -- PneumRx, Inc. (www.pneumrx.com), a medical device company dedicated to bringing innovation and improvements to the treatment of lung disease, today announced that it has expanded its intellectual property portfolio by acquiring key patents and domain names from Broncus Technologies. (Logo: http://photos.prnewswire.com/prnh/20120514/SF06703LOGO) As a result of the acquisition, PneumRx now owns numerous domain names, including...
MOUNTAIN VIEW, Calif., May 15, 2012 /PRNewswire/ -- PneumRx, Inc. (www.pneumrx.com), a medical device company dedicated to bringing innovation and improvements to the treatment of lung disease, today announced that it has received FDA approval to commence a 30-site pivotal clinical trial to support a PMA application for the RePneu LVRC System. (Logo: http://photos.prnewswire.com/prnh/20120514/SF06703LOGO) The RePneu LVRC System is a minimally invasive device intended to improve...
TUSTIN, Calif., Dec. 21, 2011 /PRNewswire/ -- Uptake Medical® today announced that it received Australian Therapeutic Goods Administration (TGA) approval for its InterVapor(TM) System for endoscopic lung volume reduction for the treatment of severe emphysema. InterVapor is the first non-surgical, endoscopic lung volume reduction system for the treatment of severe emphysema that uses the body's natural healing processes without leaving implants or foreign materials in the lung....
AMSTERDAM and TUSTIN, Calif., Sept. 26, 2011 /PRNewswire/ -- Uptake Medical® today announced it has received the CE Mark (Conformite Europeenne) for the InterVapor(TM) System - the first endoscopic lung volume reduction system for the treatment of severe emphysema that uses the body's natural healing processes without leaving foreign materials behind. The CE Mark will allow Uptake Medical to commercialize InterVapor in key markets within the European Community. This announcement...
MOUNTAIN VIEW, Calif., Jan. 4, 2011 /PRNewswire/ -- PneumRx, Inc. (www.pneumrx.com), a medical device company dedicated to bringing innovation and improvements to the treatment of lung disease, today announced that it has raised $33 million in working capital commitments. The oversubscribed round was led by Forbion Capital Partners and co-led by Endeavour Vision, both leading venture capital firms from Europe, and also included a prominent strategic corporate partner. The syndicate was...
